Get the Stockscreener App
11.19
3.71%
0.40
Prothena Corp Plc stock is traded at $11.19, with a volume of 306.80K.
It is up +3.71% in the last 24 hours and up +13.49% over the past month.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
See More
Previous Close:
$10.79
Open:
$10.89
24h Volume:
306.80K
Relative Volume:
0.64
Market Cap:
$602.39M
Revenue:
$9.68M
Net Income/Loss:
$-244.09M
P/E Ratio:
-2.4677
EPS:
-4.5346
Net Cash Flow:
$-168.85M
1W Performance:
-2.78%
1M Performance:
+13.49%
6M Performance:
+8.96%
1Y Performance:
+38.49%
1-Day Range:
$10.89
$11.25
1-Week Range:
$10.55
$11.46
52-Week Range:
$4.32
$11.69
Prothena Corp Plc Stock (PRTA) Company Profile
Name
Prothena Corp Plc
Sector
Industry
Phone
011-353-1-236-2500
Address
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Compare PRTA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRTA
Prothena Corp Plc
|
11.19 | 602.39M | 9.68M | -244.09M | -168.85M | -4.5346 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Prothena Corp Plc Stock (PRTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Downgrade | BofA Securities | Neutral → Underperform |
| May-27-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-27-25 | Downgrade | Jefferies | Buy → Hold |
| May-27-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Apr-24-23 | Initiated | SVB Securities | Outperform |
| Jan-27-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-28-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Jun-18-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-08-21 | Reiterated | Oppenheimer | Outperform |
| May-26-21 | Initiated | Citigroup | Buy |
| Feb-26-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-12-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-02-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Jul-09-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-19-19 | Upgrade | Evercore ISI | In-line → Outperform |
| May-21-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-23-18 | Downgrade | Jefferies | Buy → Hold |
| Apr-05-18 | Reiterated | Barclays | Overweight |
| Nov-20-17 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-29-17 | Reiterated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Jefferies | Buy |
| Apr-12-17 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-17 | Initiated | Piper Jaffray | Overweight |
| Mar-02-17 | Initiated | Instinet | Buy |
| Dec-21-16 | Initiated | SunTrust | Buy |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Aug-04-16 | Reiterated | Barclays | Overweight |
| May-13-16 | Initiated | Barclays | Overweight |
| Feb-19-16 | Reiterated | Wedbush | Outperform |
| Jan-21-16 | Initiated | Credit Suisse | Outperform |
View All
Prothena Corp Plc Stock (PRTA) Latest News
Prothena to Report First Quarter 2026 Financial Results on May 7 - Business Wire
3 Growth Companies Insiders Are Eager To Hold - Sahm
Prothena (NASDAQ:PRTA) Shares Up 5.9%Time to Buy? - MarketBeat
FDA Fast Track granted to Phase 3 drug for ATTR-CM - Stock Titan
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy - The Joplin Globe
Prothena authorizes up to $100 million share repurchase plan - MSN
PRTA SEC FilingsProthena 10-K, 10-Q, 8-K Forms - Stock Titan
Price vs Value Analysis | Prothena Corporation posts 29.8% EPS beat with narrower loss - Cổng thông tin điện tử tỉnh Lào Cai
PRTA (Prothena Corporation plc Ordinary Shares) rises 3.61 percent after Q4 2025 EPS outpaces analyst consensus estimates.AI Powered Stock Picks - Xã Châu Thành
Liquidity Mapping Around (PRTA) Price Events - Stock Traders Daily
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving AverageTime to Sell? - MarketBeat
Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors? - AD HOC NEWS
Prothena FY25 Earnings Review: Partnered Programs Advance Toward Milestones as Wholly-Owned Assets Pivot - AlphaStreet
Prothena Announces Leadership Team Updates - National Today
Chardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial Failure - MSN
Why (PRTA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Prothena Corp PLC (PRTA) Stock Earnings Transcripts - GuruFocus
Prothena (NASDAQ: PRTA) awards 100,000 stock options to Chief Strategy Officer - Stock Titan
Prothena (PRTA) Chief Strategy Officer reports 66,942 shares and option grants - Stock Titan
Prothena (PRTA) Strengthens Leadership Team with Key Promotions - GuruFocus
Prothena promotes Kingston, Isaacs to leadership roles - Investing.com
Prothena Corporation Announces Leadership Team Updates to Support Pipeline Development - geneonline.com
Prothena promotes Kingston, Isaacs to leadership roles By Investing.com - Investing.com India
Insider Sell: Will Prothena Corporation plc outperform tech stocksQuarterly Investment Review & Verified Swing Trading Watchlist - baoquankhu1.vn
PRTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Published on: 2026-04-07 04:52:36 - baoquankhu1.vn
Is Prothena (PRTA) Stock Trending Down | Price at $10.05, Up 1.93%Crowd Risk Alerts - Newser
Analyst Calls: How do insiders feel about Prothena Corporation plc2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Gap Down: Can Prothena Corporation plc be recession proofWeekly Trend Report & AI Driven Price Predictions - baoquankhu1.vn
Prothena Corp plc Stock: Clinical Milestones and Strategic Focus in Biotechnology Drive Investor Int - AD HOC NEWS
PRTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
PRTA Technical Analysis & Stock Price Forecast - Intellectia AI
Understanding Momentum Shifts in (PRTA) - Stock Traders Daily
Top Growth Companies With High Insider Ownership In March 2026 - simplywall.st
JPMorgan Chase & Co. Buys 608,814 Shares of Prothena Corporation plc $PRTA - MarketBeat
Aug Patterns: Will Prothena Corporation plc outperform its industry peersWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Stock Recap: Will Prothena Corporation plc benefit from rising consumer demandQuarterly Market Review & Weekly Hot Stock Watchlists - baoquankhu1.vn
Gainers Report: Will Prothena Corporation plc outperform tech stocks2026 Support & Resistance & Detailed Earnings Play Strategies - baoquankhu1.vn
Prothena (NASDAQ: PRTA) details 2026 AGM, pay and 2025 pipeline shifts - Stock Titan
When Can We Expect A Profit From Prothena Corporation plc (NASDAQ:PRTA)? - simplywall.st
Prothena Q4 earnings meet estimates, pipeline progress in focus - MSN
Published on: 2026-03-27 01:04:54 - baoquankhu1.vn
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet - sharewise.com
Dow Update: Will Prothena Corporation plc benefit from rising consumer demandEntry Point & Low Risk High Reward Trade Ideas - baoquankhu1.vn
H.C. Wainwright reiterates Prothena stock rating on Parkinson’s data By Investing.com - Investing.com UK
Prothena (NASDAQ:PRTA) Shares Cross Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Prothena Corp plc stock gains spotlight as partners Roche and Bristol-Myers Squibb showcase key clin - AD HOC NEWS
Prothena Partners Present Data Supporting Next Generation Treatme - The National Law Review
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 - Business Wire
Prothena Corp plc stock faces pressure amid biotech volatility and pipeline updates - AD HOC NEWS
Prothena Corp Plc Stock (PRTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):